Learn how robust SARS-CoV-2 testing options can help laboratories better grow serve their customers, grow their business, and protect their communities.

The SARS-CoV-2 Rapid Antigen Test is intended to detect specific antigen from the SARS-CoV-2 virus in individuals suspected of COVID-19. The test is intended for professional use only. See how it works.

Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic.

The SARS-CoV-2 Rapid Antibody Test can be used to determine whether patients have already been infected with the virus. Learn how it works.

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for anti-PD1 immunotherapy.

Since the first EU Quality Management System certificate (IVDR) was issued by our notified body, TÜV SÜD, in December 2020, all relevant Quality Management Systems have been successfully audited.

Roche today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19.

Roche launches DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

Register now for Tucson Symposium 2021, April 20–22